Odds of Hospitalization for COVID-19 After 3 vs 2 Doses of mRNA COVID-19 Vaccine by Time Since Booster Dose.
作者信息
Ridgway Jessica P, Tideman Samuel, French Thomas, Wright Bill, Parsons Guilford, Diaz George, Robicsek Ari
机构信息
Department of Medicine, University of Chicago, Chicago, Illinois.
Providence Research Network, Renton, Washington.
出版信息
JAMA. 2022 Oct 18;328(15):1559-1561. doi: 10.1001/jama.2022.17811.
Abstract
摘要
相似文献
1
Odds of Hospitalization for COVID-19 After 3 vs 2 Doses of mRNA COVID-19 Vaccine by Time Since Booster Dose.自加强剂量起，两剂与三剂mRNA新冠疫苗接种后新冠病毒疾病住院几率对比
JAMA. 2022 Oct 18;328(15):1559-1561. doi: 10.1001/jama.2022.17811.
2
Booster dose of COVID-19 mRNA vaccine does not increase risks of myocarditis and pericarditis compared with primary vaccination: New insights from the vaccine adverse event reporting system.与基础免疫相比，COVID-19 mRNA 疫苗加强针不会增加心肌炎和心包炎的风险：疫苗不良事件报告系统的新见解。
Front Immunol. 2022 Sep 12;13:938322. doi: 10.3389/fimmu.2022.938322. eCollection 2022.
3
Effectiveness of a Second COVID-19 Vaccine Booster Dose Against Infection, Hospitalization, or Death Among Nursing Home Residents - 19 States, March 29-July 25, 2022.2022 年 3 月 29 日至 7 月 25 日，19 个州养老院居民中第二剂 COVID-19 加强疫苗对感染、住院或死亡的有效性。
MMWR Morb Mortal Wkly Rep. 2022 Sep 30;71(39):1235-1238. doi: 10.15585/mmwr.mm7139a2.
4
Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022.同源和异源 COVID-19 加强针在接种 1 剂 Ad.26.COV2.S（强生[詹森]）疫苗后的有效性：成人因 COVID-19 前往急诊和紧急护理就诊和住院的情况 - VISION 网络，10 个州，2021 年 12 月至 2022 年 3 月。
MMWR Morb Mortal Wkly Rep. 2022 Apr 1;71(13):495-502. doi: 10.15585/mmwr.mm7113e2.
5
Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022.COVID-19 疫苗加强针接种后的安全性监测-美国，2021 年 9 月 22 日-2022 年 2 月 6 日。
MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):249-254. doi: 10.15585/mmwr.mm7107e1.
6
In brief: Booster doses of mRNA-based COVID-19 vaccines for all adults.简而言之：为所有成年人接种基于mRNA的新冠病毒疫苗加强针。
Med Lett Drugs Ther. 2021 Dec 27;63(1640):201-202.
7
Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021.mRNA 新冠疫苗 2 剂接种对免疫功能低下成人因 COVID-19 住院的效果-9 个州，2021 年 1 月至 9 月。
MMWR Morb Mortal Wkly Rep. 2021 Nov 5;70(44):1553-1559. doi: 10.15585/mmwr.mm7044e3.
8
Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.在德尔塔和奥密克戎变异株流行期间，mRNA 疫苗加强针在成年人中的 COVID-19 相关急诊和紧急护理就诊和住院方面的效果 - VISION 网络，10 个州，2021 年 8 月至 2022 年 1 月。
MMWR Morb Mortal Wkly Rep. 2022 Jan 21;71(4):139-145. doi: 10.15585/mmwr.mm7104e3.
9
Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines - United States, October 2022.免疫实践咨询委员会关于使用二价加强针 COVID-19 疫苗的临时建议-美国，2022 年 10 月。
MMWR Morb Mortal Wkly Rep. 2022 Nov 11;71(45):1436-1441. doi: 10.15585/mmwr.mm7145a2.
10
Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.mRNA COVID-19 疫苗 3 剂接种与 SARS-CoV-2 奥密克戎和德尔塔变异株引起的有症状感染之间的关联。
JAMA. 2022 Feb 15;327(7):639-651. doi: 10.1001/jama.2022.0470.
引用本文的文献
1
Risk reduction in SARS-CoV-2 infection and reinfection conferred by humoral antibody levels among essential workers during Omicron predominance.在奥密克戎毒株占主导期间，一线工作者体内体液抗体水平对降低新冠病毒感染及再感染风险的作用。
PLoS One. 2024 Dec 31;19(12):e0306953. doi: 10.1371/journal.pone.0306953. eCollection 2024.
2
A Narrative Review of Key Risk Factors for Severe Illness Following SARS-CoV-2, Influenza Virus, and Respiratory Syncytial Virus Infection.关于新型冠状病毒、流感病毒和呼吸道合胞病毒感染后重症关键危险因素的叙述性综述
Infect Dis Ther. 2025 Jan;14(Suppl 1):39-61. doi: 10.1007/s40121-024-01081-3. Epub 2024 Dec 30.
3
COVID-19 Vaccination Recommendations for Immunocompromised Patient Populations: Delphi Panel and Consensus Statement Generation in the United States.免疫功能低下患者群体的COVID-19疫苗接种建议：美国德尔菲小组与共识声明的制定
Infect Dis Ther. 2024 Nov;13(11):2255-2283. doi: 10.1007/s40121-024-01052-8. Epub 2024 Oct 10.
4
SARS-CoV-2 Variants and Clinical Outcomes of Special Populations: A Scoping Review of the Literature.SARS-CoV-2 变异株和特殊人群的临床结局：文献的范围综述。
Viruses. 2024 Jul 30;16(8):1222. doi: 10.3390/v16081222.
5
Effectiveness of Lianhua Qingwen Granule and Jingyin Gubiao Prescription in Omicron BA.2 Infection and Hospitalization: A Real-World Study of 56,244 Cases in Shanghai, China.连花清瘟颗粒与荆银固表方对奥密克戎BA.2感染及住院治疗的有效性：一项针对中国上海56244例病例的真实世界研究
Chin J Integr Med. 2025 Jan;31(1):11-18. doi: 10.1007/s11655-024-3901-7. Epub 2024 Jun 24.
6
Durability of the Effectiveness of Heterologous COVID-19 Vaccine Regimens in Thailand: Retrospective Cohort Study Using National Registration Data.泰国异源 COVID-19 疫苗方案有效性的持久性：使用国家登记数据的回顾性队列研究。
JMIR Public Health Surveill. 2024 Mar 5;10:e48255. doi: 10.2196/48255.
7
Investigating the Antibody Imprinting Hypothesis among Canadian Paramedics after SARS-CoV-2 Omicron Variant Circulation.调查 SARS-CoV-2 奥密克戎变异株流行后加拿大护理人员中的抗体印迹假说。
Immunohorizons. 2024 Feb 1;8(2):193-197. doi: 10.4049/immunohorizons.2400010.
8
Association Between the "We Can Do This" Campaign and COVID-19 Booster Uptake, U.S., 2021-2022.2021 - 2022年美国“我们能做到”运动与新冠病毒加强针接种率之间的关联
AJPM Focus. 2024 Jan 4;3(2):100183. doi: 10.1016/j.focus.2024.100183. eCollection 2024 Apr.
9
Changes in the intrinsic severity of severe acute respiratory syndrome coronavirus 2 according to the emerging variant: a nationwide study from February 2020 to June 2022, including comparison with vaccinated populations.根据新兴变异株，严重急性呼吸综合征冠状病毒 2 的固有严重程度的变化：一项 2020 年 2 月至 2022 年 6 月的全国性研究，包括与接种疫苗人群的比较。
BMC Infect Dis. 2024 Jan 2;24(1):1. doi: 10.1186/s12879-023-08869-7.
10
Design and analysis heterogeneity in observational studies of COVID-19 booster effectiveness: A review and case study.设计和分析 COVID-19 加强针有效性的观察性研究中的异质性：综述和案例研究。
Sci Adv. 2023 Dec 22;9(51):eadj3747. doi: 10.1126/sciadv.adj3747. Epub 2023 Dec 20.
Zotero 插件